Clinical Trial Update: Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and bioavailability of subcutaneously administered XmAb7195 in healthy volunteers and subjects with atopic disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Disease

Drugs mentioned

• XmAb7195

Snippet

Sponsor: Xencor, Inc. | Conditions: Healthy Volunteers, Atopic Disease | Phase 1 | Status: COMPLETED